Oct 2012 intergrative medicine isaac eliaz

365 views

Published on

Published in: Health & Medicine, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
365
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • The Prevention of Renal and Vascular End-stage Disease (PREVEND) study results were presented at the European Society of Cardiology (ESC) Congress (Aug)2011, in Paris, France. “Galectin-3, Cardiovascular Risk Factors and Outcome in the General Population,” presented by Rudolf de Boer, MD, PhD, Associate Professor in Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • Najmeh T, Houri S, Parvin M, Firouzeh B, Arash HN, Abdolfattah S, Ebrahim H. Combination effect of pectasol and doxorubicin on viability, cell cycle arrest and apoptosis in DU-145 and LNCaP prostate cancer cell Lines.Cell Biology International (2012) doi:10.1042/CBI20110309.Wang Y, Nangia-Makker P, Balan V, Hogan V, Raz A. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.Cell Death Dis. 2010 Nov18;1(11):e101.)
  • 20.
  • The Prevention of Renal and Vascular End-stage Disease (PREVEND) study results were presented at the European Society of Cardiology (ESC) Congress (Aug)2011, in Paris, France. “Galectin-3, Cardiovascular Risk Factors and Outcome in the General Population,” presented by Rudolf de Boer, MD, PhD, Associate Professor in Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • The Prevention of Renal and Vascular End-stage Disease (PREVEND) study results were presented at the European Society of Cardiology (ESC) Congress (Aug)2011, in Paris, France. “Galectin-3, Cardiovascular Risk Factors and Outcome in the General Population,” presented by Rudolf de Boer, MD, PhD, Associate Professor in Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • The Prevention of Renal and Vascular End-stage Disease (PREVEND) study results were presented at the European Society of Cardiology (ESC) Congress (Aug)2011, in Paris, France. “Galectin-3, Cardiovascular Risk Factors and Outcome in the General Population,” presented by Rudolf de Boer, MD, PhD, Associate Professor in Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • The Prevention of Renal and Vascular End-stage Disease (PREVEND) study results were presented at the European Society of Cardiology (ESC) Congress (Aug)2011, in Paris, France. “Galectin-3, Cardiovascular Risk Factors and Outcome in the General Population,” presented by Rudolf de Boer, MD, PhD, Associate Professor in Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.
  • Put MCP Table in
  • Put MCP Table in
  • Oct 2012 intergrative medicine isaac eliaz

    1. 1. • • •
    2. 2. Hands on Healing Asian Medicine Western Medicine Acupuncture Nutrition
    3. 3. • • • •
    4. 4. • • • • • •
    5. 5. • •
    6. 6. • • • • • • •
    7. 7. • • • • • • •
    8. 8.
    9. 9. • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
    10. 10. • Patterns of Prostate Cancer • Physiological vs. Pathological • Maintenance vs. Cure • Supplements & Adjuvant Therapy
    11. 11. • • • • • •
    12. 12. • Biopsy • Watchful Waiting • Local Therapy • Hormonal Therapy • Androgen Independent • Advanced Disease
    13. 13. • • • •
    14. 14. • • • • • •
    15. 15. • • • • •
    16. 16. • • • • • • • •
    17. 17. • • • • • • • •
    18. 18. • • • • • • • •
    19. 19. • Biologically active marker for high risk • Unlike CRP which represents the result or “ ” biomarker, Galectin-3 is a “culprit” biomarker • Promotes metastasis, inflammation & fibrosis • Predicts outcome
    20. 20. • • • • • • • •
    21. 21. • • • • • • •
    22. 22. Blood Vessel
    23. 23. Blood Vessel
    24. 24. • • • •
    25. 25. • • • •
    26. 26. • • • • •
    27. 27. • • • •
    28. 28. • • • • • • •
    29. 29. • • 0% 20% 40% 60% 80% 100% Control 0.1% 1.0% 3.8% 76.9% 80.7% %Cytotoxicity .
    30. 30. 0% 10% 20% 30% 40% 50% 60% 70% 80% No Response Stable Disease Response 14% 14% 71% %IncreaseinPSADT • •
    31. 31. • •
    32. 32. MCP
    33. 33. • • • • • • • •
    34. 34. • • • •
    35. 35. • • • • • •
    36. 36.
    37. 37. • • • •
    38. 38. • • • • • • • • •
    39. 39. • • • • • •
    40. 40. • • •
    41. 41. • • • •
    42. 42. • • • • •
    43. 43. • •
    44. 44. • • • • •
    45. 45. • •
    46. 46. • • •
    47. 47. P Value = 0.0016
    48. 48. P Value = 0.0007
    49. 49. • • • •
    50. 50. 24 hours 48 hours 72 hours ProliferationIndex(%) 0 20 40 60 80 100 120 0 g/ml 10 g/ml 20 g/ml 40 g/ml 80 g/ml* * * * * * * * * **
    51. 51. Effect of ProstaCaid on Invasive Behavior of Prostate Cancer Cells 0 20 40 60 80 100 120 0 20 40 80 Cellinvasion[%] ProstaCaid [g/ml] * * 0 20 40 60 80 100 120 0 20 40 80 Cellmigration[%] ProstaCaid [g/ml] * * 0 20 40 60 80 100 120 0 20 40 80 Celladhesion[%] ProstaCaid (g/ml) * * A B C D uPA 0 20 40 80 ProstaCaid ( g/ml) 1.00 0.61 0.38 0.16 uPA Density (A) Cell adhesion. PC-3 cells were treated with ProstaCaid for 24 hours and cell adhesion to fibronectin determined. (B) Cell migration. Cell migration was determined after 24 hours of incubation with ProstaCaid in Boyden Chambers. (C) Cell invasion. Cell invasion was determined after 24 hours of incubation with ProstaCaid in Boyden Chambers coated with Matrigel. (D) uPA secretion. PC-3 cells were treated for 24 hours and the expression of uPA detected in conditioned media with anti-uPA antibody by Western blot. * p<0.05
    52. 52.
    53. 53. • • • •
    54. 54. 24 hours 48 hours 72 hours ProliferationIndex[%] 0 20 40 60 80 100 120 0g/ml 10 g/ml 20 g/ml 30 g/ml 40 g/ml * * * * ** * * * *
    55. 55. • Method: Highly aggressive triple negative human breast cancer cells (MDA-MB-231) implanted into the mammary gland in mice then given the formula orally (100 mg/kg of body weight for 4 weeks) for four weeks. • Results: The formula significantly decreased tumor growth and breast to lung metastasis, and did not affect body weight or activity of liver enzymes or show any sign of toxicity in liver spleen, kidney, lung and heart tissues in mice. • The cancer metastasized to the lungs in 67 percent of controls but only 20 percent of treated mice. The number of metastases per animal was also significantly affected by the formula. • Down-regulation of primary tumor genes PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4). BreastDefend Suppresses MDA-MB-231 Growth and Breast-to-Lung Metastasis in a Orthotopic Tumor Model (poster at AACR April 2012) Jiang J, Thyagarajan-Sahu A, Loganathan J, Eliaz I, Terry C, Sandusky GE, Sliva D. Oncol Rep. 2012; 28: 1139-1145.
    56. 56. ProliferationIndex(%).
    57. 57. %Migration 0 20 40 60 80 100 120 P<0.01 P<0.01 P<0.01 MCP 0 0.25 0.5 1.0 0 0.25 0.5 1.0 mg/ml ProstaCaid 10 10 10 10 g/ml The invasive behavior of PC3 evaluated using migration assay in the presence of (A) MCP (mg/mL) & (B) MCP (mg/mL) plus Prostacaid (10 ug/mL).
    58. 58. 0 20 40 60 80 100 120 0 5 10 20 40 ProliferationIndex(%) Growth of MDA-MB-231 measured using MTT assay. MDA-MB-231 cells incubated for 24 hrs BreastDefend(ug/mL) at the indicated concentrations. *P < .05
    59. 59. MCP 0 0.25 0.5 1.0 0 0.25 0.5 1.0 mg/ml BreastDefend 20 20 20 20 g/ml %Migration 0 20 40 60 80 100 120 P<0.01 P<0.01 P<0.01
    60. 60. • • • • • • • • • • •
    61. 61. Mechanisms of Action • Modulation of GABA receptors • Blocks signaling in tumors with defective p53 function and ras by blocking activation of phospholipase D • Induces cyclophilin D, potentiating mitochondrial permeability transition pore and causing death in cells with wild-type p53 • MTOR-1 Inhibitor
    62. 62. • • •
    63. 63. • • •
    64. 64. • Apoptosis induced by Magnolia Grandiflora extract in chlorambucil-resistant B-chronic lymphocytic leukemia cells. Marin GH, Mansilla E. J Cancer Res Ther. 2010 Oct-Dec;6(4):463-5. • Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX- 5): implications for natural sedatives as chemosensitizing agents in cancer therapy. Angelini A, Di Ilio C, Castellani ML, et al. J Biol Regul Homeost Agents. 2010 Apr- Jun;24(2):197-205. • Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells. Wang Y, Yang Z, Zhao X. Toxicol Mech Methods. 2010 Jun;20(5):234- 41.
    65. 65. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Nephro-Urology Unit, UCL Institute of Child Health, London, UK PLoS ONE 2011 April 6(4): e18683.
    66. 66. • • • • • •
    67. 67. Overall 11.9 Galectin-3 Levels & from All Causes in the General Population: PREVEND
    68. 68. CHARACTERISTIC Median Gal3 TOTAL 11.9 QUINTILE-1 7.7 QUINTILE-2 9.4 QUINTILE-3 10.9 QUINTILE-4 12.6 QUINTILE-5 15.6 P DM% 3.6 2.3 2.3 3.1 4.3 6.1 0.000 MI 3.7 1.8 2.4 2.7 4.2 7.4 0.000 Hypertension 33.4 22.2 26.6 31.1 39.7 47.9 0.000 Stroke % 0.9 0.8 0.6 0.6 1.3 1.6 0.004 Systolic BP 129.2 20.2 125.0 18.1 126.6 19.0 128.6 19.6 131.3 20.6 134.9 22.5 0.000 Diastolic BP 74.0 9.7 72.1 9.4 73.3 9.8 74.1 9.6 75.2 9.8 75.4 9.8 0.000
    69. 69. CHARACTERISTIC Median Gal3 TOTAL 11.9 QUINTILE-1 7.7 QUINTILE-2 9.4 QUINTILE-3 10.9 QUINTILE-4 12.6 QUINTILE-5 15.6 P CRP 1.29 [0.56-3.00] 0.89 [0.39-2.16] 1.04 [0.49-2.40] 1.33 [0.58-2.92] 1.53 [0.71-3.42] 1.98 [0.85-4.28] 0.000 Cholesterol 5.66 1.12 5.41 1.05 5.56 1.10 5.68 1.11 5.79 1.11 5.91 1.17 0.000 LDL 3.69 1.05 3.47 1.00 3.60 1.01 3.71 1.04 3.77 1.05 3.90 1.06 0.000 HDL 1.27 [1.03+1.56] 1.32 [1.07-1.62] 1.28 [1.04-1.57] 1.25 [1.03+1.55] 1.24 [1.03-1.53] 1.24 [0.99-1.52] 0.000 Triglycerides 1.16 [0.85-1.68] 1.02 [0.75-1.43] 1.11 [0.82-1.59] 1.17 [0.86-1.69] 1.23 [0.89-1.78] 1.31 [0.95-1.92] 0.000
    70. 70. Overall 11.9 Galectin-3 & Mortality from All Causes in the General Population: PREVEND
    71. 71. COACH Galectin-3 Sub-Study Mortality from All Causes at 1 Year in Patients with CHF
    72. 72. • • • • •
    73. 73. • • •
    74. 74. • Test for Galectin-3 levels • Address general inflammation & hyperviscosity • Use MCP at appropriate dosages by: • Condition • Galectin-3 levels • Therapeutic goal
    75. 75. • • • • •
    76. 76.
    77. 77.
    78. 78. • •
    79. 79. • Desired levels <12.0 ng/ml • Follow up on Galectin-3 levels routinely every 3-6 months Galectin-3 Levels: Cancer
    80. 80. • • •
    81. 81. • • •
    82. 82. • •
    83. 83. • Levels < 12.0 ng/ml MCP 5g daily • Levels = 12.0 – 14.0 ng/ml MCP 10g daily • Levels = 14.0 – 17.8 ng/ml MCP 15g daily • Levels >17.8 ng/ml MCP 20 – 25g daily Cancer Long Term Maintenance (3 years post therapy)
    84. 84. • •
    85. 85. • • • • •
    86. 86. • • •
    87. 87. • • •
    88. 88. ±
    89. 89. • • • •
    90. 90. • • • • • • •
    91. 91. • • • • • • • •
    92. 92. • • • • • • • • •
    93. 93. • • • • • • •
    94. 94.
    95. 95. • • • • • • • • • •
    96. 96. • •
    97. 97. • • • • • • • • • • • •
    98. 98. • • • • • •
    99. 99. • • •
    100. 100. • • • • • • •
    101. 101. • • • • • • • •
    102. 102. • • • •
    103. 103. • • • • • •
    104. 104. • • •
    105. 105. • • • •

    ×